A recent study investigated the mechanisms underlying the interaction between olaparib and cediranib in non--mutant ovarian cancer. Cediranib may confer sensitivity to olaparib by increasing tumor hypoxia and inhibiting platelet-derived growth factor receptor, which reduces and expression, thus decreasing homology-deficient DNA repair.